{"classes":[{"categories":[{"measurements":[{"comment":"These were Kaplan-Meier estimates. Median and/or upper limit of CI was not estimable because a small proportion of responders either progressed or died due to progressive disease.","groupId":"OG000","lowerLimit":"1.8","upperLimit":"NA","value":"NA"},{"comment":"These were Kaplan-Meier estimates. Median and/or upper limit of CI was not estimable because a small proportion of responders either progressed or died due to progressive disease.","groupId":"OG001","lowerLimit":"5.5","upperLimit":"NA","value":"7.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"Duration of response was calculated from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in IMWG criteria. Disease progression (IMWG criteria): increase of 25 percent (%) from lowest response level in Serum M-component (the absolute increase must be \\>=0.5 g/dL) and/or; urine M-component (the absolute increase must be \\>=200 mg/24 hours) and/or; only in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain levels (absolute increase must be \\>10 milligram per deciliter (mg/dL); Development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL or 2.65 millimole per liter \\[mmol/L\\]) that can be attributed solely to the plasma cell proliferative disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab 8 milligram per kilogram (mg/kg) every 4 weeks (Q4W) until disease progression or unacceptable toxicity.","id":"OG000","title":"Daratumumab 8 mg/kg"},{"description":"Daratumumab 16 mg/kg weekly for 8 weeks; then every 2 weeks (Q2W) for 16 weeks; then Q4W until disease progression or unacceptable toxicity.","id":"OG001","title":"Daratumumab 16 mg/kg"}],"paramType":"MEDIAN","populationDescription":"Responders in all treated analysis set. Only those participants with confirmed PR and those who experienced progressive disease were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to 14.4 Months","title":"Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}